GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Phentermine/topiramate ER (QSYMIA)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Qsymia

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Missing RX dose subsection filled by exact DailyMed label

The selected RX retrieval supplied pharmacokinetics but not the renal dose ceiling. The exact DailyMed dose subsection is now included locally.

Before applying: Read the official renal dose ceiling; the remaining full-label precautions still apply.

Also check: Missing RX dose subsection filled by exact DailyMed label

Official source

QSYMIA - phentermine/topiramate ER capsules

Product / population
QSYMIA fixed-combination extended-release capsules; renal ceiling, not a starting-dose or taper schedule.
Renal measure
CrCl by Cockcroft-Gault using actual body weight, mL/min.

Renal dosing, restrictions and evidence limits

For CrCl below 50 mL/min, the maximum is phentermine 7.5 mg/topiramate 46 mg orally once daily. For CrCl 50 to less than 80, the usual regimen may be used. Avoid use in end-stage renal disease on dialysis. Keep the initial titration, pregnancy-prevention requirements, contraindications, and discontinuation precautions from the full label; the renal ceiling is not an instruction to start at that dose.

Source revision: Revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9

Scope: Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

QSYMIA - phentermine/topiramate ER capsules

QSYMIA fixed-combination extended-release capsules; renal ceiling, not a starting-dose or taper schedule.

Renal method: CrCl by Cockcroft-Gault using actual body weight, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Qsymia

Pharmacokinetic observation only. Do not convert an exposure finding into an unverified dose.

Fixed combination; selected pharmacokinetic source subsection only. Renal dose subsection was not available in the retrieved page body.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

retrieval gap

Missing RX dose subsection filled by exact DailyMed label

The selected RX retrieval supplied pharmacokinetics but not the renal dose ceiling. The exact DailyMed dose subsection is now included locally.

How to use this: Read the official renal dose ceiling; the remaining full-label precautions still apply.

GlobalRPh RX List - QsymiaQSYMIA - phentermine/topiramate ER capsules

Source difference identified; final patient-specific adjudication required.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeQSYMIA - phentermine/topiramate ER capsulesGlobalRPh RX List - Qsymia
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/qsymia-drug/

Product and population scope

Fixed combination; selected pharmacokinetic source subsection only. Renal dose subsection was not available in the retrieved page body.

RDM33-SCOPE-phentermine-topiramate-qsymia-C1 · Source section: Exact product identity and selected populationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

QSYMIA - phentermine/topiramate ER capsules

Open original reference

Open / share this exact local source

DailyMed / NLM; manufacturer prescribing information · QSYMIA fixed-combination extended-release capsules; renal ceiling, not a starting-dose or taper schedule.

Renal method: CrCl by Cockcroft-Gault using actual body weight, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For CrCl below 50 mL/min, the maximum is phentermine 7.5 mg/topiramate 46 mg orally once daily. For CrCl 50 to less than 80, the usual regimen may be used. Avoid use in end-stage renal disease on dialysis. Keep the initial titration, pregnancy-prevention requirements, contraindications, and discontinuation precautions from the full label; the renal ceiling is not an instruction to start at that dose.

RDM33-official-phentermine-topiramate-qsymia-C1 · Source locator: Sections 2.4 and 8.6.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9
Retrieved
2026-09-07
Exact label title
QSYMIA - phentermine/topiramate ER capsules
DailyMed Set ID
40dd5602-53da-45ac-bb4b-15789aba40f9
Renal-function method
CrCl by Cockcroft-Gault using actual body weight, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
d2cbdcec389b205e8e68346d93c8206e01950bf5e8b13f1d309ef71819792e72
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Qsymia

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Fixed combination; selected pharmacokinetic source subsection only. Renal dose subsection was not available in the retrieved page body.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. Do not convert an exposure finding into an unverified dose.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The source describes increased exposure to both components with declining renal function. Its study groups were CrCl 50 to less than 80, 30 to less than 50, and below 30 mL/min. Patients with end-stage renal disease on dialysis were not studied. A dose ceiling is not imported from this pharmacokinetic section; the missing prescribing subsection requires follow-up.

RDM33-rxlist-phentermine-topiramate-qsymia-C1 · Source locator: Clinical pharmacology: patients with renal impairment.

Source-specific limits

Dose-section gap explicitly retained; do not interpret as no renal adjustment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/qsymia-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
3b282a4ec4faf0fc278fbc95fb2b490077df7c0eaaf5b2821dbc85aa3238518c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/qsymia-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
825fc3308bde3022249a34fa5f0be26b9b35a7ec64cd0b01930aa31d765ac9c2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report